Occult atherosclerosis and physical vascular examination: A simple strategy to avoid inadequate cardiovascular prevention and under-use of diagnostic vascular guidelines in outpatients. A multicenter study by Angiology Care Units in North-Eastern Italy

International Angiology

Volumn 27, Issue 5, 2008, Pages 426-432

  Marzolo, Marco ^a   Verlato, F ^a   Zotta, L ^a   Guadagnin, M L ^b   Borgese, L ^c   Cravatari, M ^d   Nardi, M ^a   Camporese, G ^a   Andreozzi, G M ^a  

^a UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^b Hospital of Thiene   (Italy)

^c De Gironcoli Hospital of Conegliano   (Italy)

^d UNIVERSITY OF TRIESTE   (Italy)

Author keywords

Atherosclerosis; Cardiovascular diseases, prevention and control; Guidelines

Indexed keywords

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; BODY WEIGHT; CARDIOVASCULAR SYSTEM EXAMINATION; CAROTID ARTERY BRUIT; CIGARETTE SMOKING; FEMALE; GLYCEMIC CONTROL; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; ITALY; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; PHYSICAL EXAMINATION; PRACTICE GUIDELINE; PREVALENCE; PRIMARY PREVENTION; PULSE WAVE; RISK FACTOR; SECONDARY PREVENTION;

AGED; AGED, 80 AND OVER; AMBULATORY CARE; ATHEROSCLEROSIS; COHORT STUDIES; FEMALE; GUIDELINE ADHERENCE; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; ITALY; MALE; MIDDLE AGED; OBESITY; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS; SMOKING;

EID: 56749136430     PISSN: 03929590     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Qureshi AI, Suri MF, Guterman LR, Hopkins LN. Ineffective secondary prevention in survivors of cardiovascular events in the US population. Arch Intern Med 2001;161:1621-8.
2. Qureshi AI, Fareed KS, Kirmani JF, Divani AA. The relative impact of inadequate primary and secondary prevention on cardiovascular mortality in the United States. Stroke 2004;35:2346-50.
3. Hlatky MA. Underuse of evidence-based therapies. Circulation 2004;110:644-5.
4. Corti MC, Guralnik JM, Sartori L, Baggio G, Manzato E, Pezzotti P et al. The effect of cardiovascular and osteoarticular diseases on disability in older Italian men and women: rationale, design, and sample characteristics of the Progetto Veneto Anziani (PRO.VA.) study. J Am Geriatr Soc 2002;50:1535-40.
5. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145-53. Erratum in: 2000;342:1376. N Engl J Med 2000;342:748.
6. Fox KM; EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362:782-8.
7. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischemic attack. Lancet 2001;358:1033-41.
8. Lonn EM, Yusuf S, Dzavik V, Doris C, Yi Q, Moore-Cox A et al. Effects of ramipril and vitamin E on atherosclerosis: the Study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation 2001;103:919-25.
9. Lindholm LH, Ibsen H, Dahlöf B, Devereux RB, Beevers G, de Faire U et al.; LIFE Study Group. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:1004-10.
10. Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B et al.; SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003;21:875-86.
11. Neal B, Mc Mahon S, Chapman N. Effects of ACE-Inhibitors, calcium antagonists and other blood-pressure-lowering drugs. Lancet 2000;356:1955-64.
12. Grundy SM, Cleeman JI, Noel Bairey Merz C, Bryan Brewer H, Clark LT, Hunninghake DB et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation 2004;110:227-39.
13. European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003;21:1011-53. Erratum in: J Hypertens 2003;21:2203-4. J Hypertens 1994;22:435.
14. Grundy SM, Cleeman JI, Noel Bairey Merz C, Bryan Brewer H, Clark LT, Hunninghake DB et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation 2004;110:227-39.
15. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22. Summary for patients in: Curr Cardiol Rep 2002;4:486-7.
16. Sheperd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM et al. (PROSPER Study Group). Pravastatin in elderly individuals at risk of vascular diesase: a randomised controlled trial. PROspective Study of Pravastatin in the Elderly at Risk. Lancet 2002;360:1623-30.
17. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 2002;288:2998-3007.
18. Sever PS, Dahlof B, Poulter NL, Wedel H, Beevers G, Caulfield M et al. ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomized controlled trial. Lancet 2003;361:1149-58.
19. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R et al. Pravastatin or Atorvastatin Evaluation and Infection Therapy-Trombolysis in Myocardial Infarction 22 Investigators (PROVE IT-TIMI 22). Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-504.
20. Gruppo collaborativo SPREAD (Stroke PRevention And Educational awareness Diffusion). Ictus cerebrale: linee guida italiane. Milano: Hyperphar Group SpA; 2003.
21. Ashton HA, Buxton MJ, Day NE, Kim LG, Marteau TM, Scott RA et al.; Multicentre Aneurysm Screening Study Group. The Multicentre Aneurysm Screening Study (MASS) into the effect of abdominal aortic aneurysm screening on mortality in men: a randomised controlled trial. Lancet 2002;360:1531-9.
22. Jarman B, PhD, FRCP, FRCGP, FFPHM, FmedSci. The Multicentre Aneurism Screening Study Group. The Multicentre Aneurism Screening Study (MASS) into the effect of abdominal aortic aneurysm screening on mortality in men: a randomised controlled trial. Lancet 2002 Nov 16; 360: 1531-9.
23. Crow P, Shaw E, Earnshaw JJ, Poskitt KR, Whyman MR, Heather BP. A single normal ultrasonographic scan at age 65 years rules out significant aneurysm disease for life in men. Br J Surg 2001;88:941-4.
24. Scott RA, Bridgewater SG, Ashton HA. Randomized clinical trial of screening for abdominal aortic aneurysm in women. Br J Surg 2002;89:283-5.
25. Strandness DE Jr, Bell JW. Peripheral vascular disease: diagnosis and evaluation using a mercury strain gauge. Ann Surg 1965;161 Suppl 4:1-35.
26. Dormandy JA, Rutherford RB. Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter-Society Consensus (TASC). J Vasc Surg 2000;31(1 Pt 2):S1-S296.
27. Hiatt WR, Medical treatment of peripheral arterial disease and claudication. N Eng J Med 2001;344:1608-21.
28. Tierney S, Fennessy F, Hayes DB. ABC of arterial and vascular disease. Secondary prevention of peripheral vascular disease. BMJ 2000;320:1262-5.
29. Consensus on Intermittent Claudication. Abano Terme (PD), Italy, 7th May 2005. (Writing Committee: Andreozzi GM, Arosio E, Martini R, Verlato F, Visonà A). Milano Roma: Wolters Kluwer Health; 2006.
30. Agnelli G, Cimminiello C, Meneghetti G, Urbinati S; PATHOS Invetigators. Prevalence and impact on clinical outcome of concomitant peripheral arterial disease (PAD) in patients with coronary and cerebrovascular disease: the PATHOS project. J Thromb Haemost 2003;1 Suppl 1:P0520.
31. O'Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK Jr et al. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. N Engl J Med 1999;340:14-22.
32. Bots ML, Dijk JM, Oren A, Grobbee DE. Carotid intima-media thickness, arterial stiffness and risk of cardiovascular disease: current evidence. J Hypertens 2002;20:2317-25.
33. Bots ML, de Jong PT, Hofman A, van Es GA, Grobbee DE. Left, right, near or far wall common carotid intima-media thickness measurements: association with cardiovascular disease and lower extremity arterial atherosclerosisi. J Clin Epidemiol 1997;50:801-7.
34. Spence JD, Eliasziw M, DiCicco M, Hackam DG, Galil R, Lohmann T. Carotid plaque area: a tool for targeting and evaluating vascular preventive therapy. Stroke 2002;33:2916-22.
35. Scott RA, Vardulaki KA, Walker NM, Day NE, Duffy SW, Ashton HA. The long-term benefits of a single scan for abdominal aortic aneurysm (AAA) at age 65. Eur J Vasc Endovasc Surg 2001;21:535-40.
36. Final report on the aspirin component of the ongoing Physicians' Health Study. Steering Committee of the Physicians' Health Study Research Group. N Engl J Med 1989;321:129-35.
37. Plan and operation of the Third National Health and Nutrition Examination Survey, 1988-94. Series 1: programs and collection procedures. Vital Health Stat 1 1994;:1-407.
38. EUROASPIRE Study Group. EUROASPIRE: a European Society of Cardiology survey of secondary prevention of coronary heart disease, principal results. Eur Heart J 1997;18:1569-82.
39. EUROASPIRE II Study Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries: principal results from EUROASPIRE II. Eur Heart J 2001;22:554-72.
40. Goldstein LB, Adams R, Furberg CD, Gorelick PB, Hademenos G, Hill M et al. Primary prevention of ischemic stroke: a statement for healthcare professionals from the stroke council of the American Heart Association. Stroke 2001;32:280.
41. Pickering TG, Daichi Shimbo DP, Haas D. Ambulatory blood pressure monitoring. N Engl J Med 2006;354:2368-74.
42. Jauhar S. The demise of the physical exam. N Engl J Med 2006;354:548-51.
43. Stafford RS, Monti V, Ma J. Underutilization of aspirin persists in US ambulatory care for the secondary and primary prevention of cardiovascular disease. PLoS Med 2005;2:e353.